Quote | Design Therapeutics Inc. (NASDAQ:DSGN)
Last: | $4.41 |
---|---|
Change Percent: | 0.22% |
Open: | $4.49 |
Close: | $4.41 |
High: | $4.545 |
Low: | $4.37 |
Volume: | 121,302 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Design Therapeutics Inc. (NASDAQ:DSGN)
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in H...
2024-05-07 13:24:31 ET More on Design Therapeutics Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design T...
Message Board Posts | Design Therapeutics Inc. (NASDAQ:DSGN)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Design Therapeutics Inc. Company Name:
DSGN Stock Symbol:
NASDAQ Market:
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in H...
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conf...
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern arou...